Navigation Links
Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
Date:6/26/2012

AUSTIN, Texas, June 26, 2012 /PRNewswire/ -- Prodigy Health Supplier entered a Joint Venture with Stason Pharmaceuticals to bring a diverse line of quality generic pharmaceuticals to the U.S. market. This relationship represents a combined commitment to providing the highest quality generic drugs with a consistent supply and a competitive price.

The partnership supports robust research and development with 30 PhDs on staff and over 120 people in that department. Core generic therapeutic categories include oncology, central nervous system (CNS), cardiovascular and dermatologic indications. Delivery mechanisms for the drugs include capsules and oral solids as well as new delivery mechanisms.

Bryan Sanders, president of Prodigy Health Supplier, states, "Quality manufacturing in Stason will provide excellent long term value to our business as well as the generic pharmaceutical market. Three of our current registrations are found on the national FDA shortage list and we are dedicated to bringing these products to market as soon as possible to help alleviate this strain. There are 7 drugs in our present pipeline that will be released over the next two years and we are evaluating additional items on the shortage list for potential registration and production."

Prodigy Health Supplier Corporation (PHS), a privately held company, was established in 2001 and is based in Austin, Texas. Since inception PHS has been a consistent and dependable supplier in the bio-pharmaceutical industry and has grown into one of the leading suppliers of plasma derivatives and injectables in the United States. PHS launched their generics division in 2010 and partners with proven manufacturers to provide a strong portfolio of generic drugs to the U.S. market. More information about PHS can be found at www.phscorporation.com.

Stason Pharmaceuticals, Inc., established in 1994 and based in Irvine, CA is a privately-held, global pharmaceutical company involved in drug development, manufacturing, importation/exportation, licensing and marketing of both generic and branded products. The company's primary area of development is in the area of oncology, and supportive products for the treatment of side effects related to cancer therapy. Additional therapeutic areas include cardiovascular, central nervous system, autoimmune and endocrine disorders. Additional information about Stason can be found at www.stasonpharma.com.


'/>"/>
SOURCE Prodigy Health Supplier Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. HealthWarehouse.com and Northwest Physicians Network Partner to Provide Exclusive Discount Pharmacy Services to Patients
3. Double Helix Joins McCann Health
4. Prostate Cancer and Bone Health
5. HealthWarehouse.com Reports 82% Year-Over-Year Revenue Growth
6. Billians HealthDATA Expands Market Coverage to Include Physician Group Practices
7. Vocollect Healthcare Systems And Prime Care Technologies Bring AccuNurse Key Performance Metrics To Long-Term Care Providers Via primeVIEW Digital Dashboard
8. U.S. News & World Report and Pharmacy Times Announce "Top Recommended Health Products"
9. ZO Skin Health, Inc. Sues Third-Party Pirates Over Illegal Sales of its Products
10. Lifescript Launches New Online Asthma Health Center
11. Gateway Foundation Warns K2 is Bad News: K2 Poses Serious Health Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):